BrainCheck has raised an additional $13 million in Series A financing to expand its enterprise cognitive care infrastructure and advance AI-assisted clinical capabilities. The round was led by Next Coast Ventures, with participation from S3 Ventures and UPMC Enterprises.
The Austin- and New York-based company develops a digital platform for cognitive assessment and care, anchored by BrainCheck Assess™, its FDA Class II digital cognitive assessment. The funding will support deeper workflow integration, longitudinal patient monitoring, population-scale deployment across primary care and specialty settings, and AI-assisted infrastructure tailored for value-based and risk-bearing healthcare environments.
BrainCheck is also expanding partnerships with collaborative care organizations to operationalize cognitive care within practices that lack the staffing or infrastructure to execute comprehensive workflows. These partnerships extend the company’s model beyond assessment into structured, scalable cognitive care pathways that combine digital tools with operational enablement.
The platform is currently used by more than 500 healthcare organizations nationwide, with clinicians completing over 640,000 cognitive assessments using BrainCheck Assess™. The system includes 29 validated cognitive screeners and care planning tools designed for standardized, repeatable measurement and longitudinal tracking. Testing protocols are customizable and available in English and Spanish, and are integrated into electronic health record systems.
As healthcare shifts toward value-based care and risk-sharing models, standardized cognitive assessment is increasingly serving as an entry point to earlier identification of mild cognitive impairment and dementia-related diseases, including Alzheimer’s disease. BrainCheck’s infrastructure is designed to support population-scale cognitive care by enabling earlier risk identification, objective measurement over time, AI-assisted longitudinal analysis, and coordinated care across clinical teams.
The company said its approach focuses on reducing operational friction in time-constrained clinical environments while ensuring that clinical interpretation and decision-making remain physician-directed.
KEY QUOTES
“Cognitive health is becoming a greater priority across the healthcare system, and the infrastructure supporting it must evolve as well. BrainCheck is contributing to that evolution by bringing greater consistency, objectivity, and longitudinal insight into cognitive care. We’re excited to support the company’s next phase of growth.”
Mike Smerklo, Co-Founder and Managing Partner of Next Coast Ventures
“UPMC clinicians have been evaluating BrainCheck for several years and have seen firsthand how standardized digital cognitive assessment can support them in real-world practice. We look forward to our continued engagement with BrainCheck and bringing it to more clinicians supporting patients who could benefit from earlier detection, long-term monitoring, and scalable cognitive care within and beyond our health system.”
Adele Towers, M.D., M.P.H., UPMC Geriatrician and Senior Clinical Advisor to UPMC Enterprises
“This capital allows us to continue building tools and workflows that fit how clinicians actually practice. We are focused on reducing friction in cognitive assessment, supporting longitudinal care, and using AI responsibly to assist, never replace, clinical decision-making.”
Chris Loughlin, Chief Executive Officer of BrainCheck
“Physicians have limited time to address cognitive care. Accountable Care Organizations and value-based care models are increasingly responsible for identifying cognitive impairment earlier and managing it longitudinally across large patient populations. We are seeing the emergence of collaborative care structures designed to support that accountability. BrainCheck provides the standardized, scalable infrastructure that enables these models to operate effectively.”
Stephen Bekanich, M.D., Chief Medical Officer of BrainCheck
